<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10070901</article-id><article-id pub-id-type="pmc">2362688</article-id><article-id pub-id-type="pii">6690157</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690157</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ueoka</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tabata</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kiura</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shibayama</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gemba</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Segawa</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chikamori</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Yonei</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hiraki</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Harada</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1">Second Department of Medicine, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan</aff><aff id="aff2">Department of Medicine, National Shikoku Cancer Center, 13 Horinouchi, Matsuyama, 790-0007, Japan</aff><aff id="aff3">Department of Medicine, Okayama Rosai Hospital, 1-10-25 Chikkoumidorimachi, Okayama, 702-8055, Japan</aff><aff id="aff4">Department of Respiratory Medicine, National Okayama Hospital, 2-13-1 Minamigata, Okayama, 700-0807, Japan</aff><aff id="aff5">Department of Medicine, Okayama Red Cross, Hospital, 65-1 Aoe, Okayama, 700-0941, Japan</aff></contrib-group><pub-date pub-type="ppub"><month>2</month><year>1999</year></pub-date><volume>79</volume><issue>5-6</issue><fpage>984</fpage><lpage>990</lpage><history><date date-type="received"><day>18</day><month>02</month><year>1998</year></date><date date-type="rev-recd"><day>14</day><month>07</month><year>1998</year></date><date date-type="accepted"><day>03</day><month>08</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-11 to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease of small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m<sup>&#x02212;2</sup> and given by 1-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m<sup>&#x02212;2</sup>, and the dose was escalated by an increase of 10 mg m<sup>&#x02212;2</sup>. The maximally tolerated dose of CPT-11 was determined as 60 mg m<sup>&#x02212;2</sup> because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76&#x00025; for NSCLC and 100&#x00025; for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m<sup>&#x02212;2</sup> and 60 mg m<sup>&#x02212;2</sup> respectively. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>phase I study</kwd><kwd>irinotecan</kwd><kwd>cisplatin</kwd><kwd>small-cell lung cancer</kwd><kwd>non-small-cell lung cancer</kwd></kwd-group></article-meta></front></article>
